Study of KNT-0916 for advanced solid tumors with FGFR2 changes
Part of Cancer clinical trials.
This study tests a new drug, KNT-0916, for people with advanced solid tumors that have a specific change in the FGFR2 gene. It may be an option if other treatments haven't worked or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor has a specific change in the FGFR2 gene (found through a blood or tumor test).
- You have tried at least one standard treatment, or you cannot take standard treatments, or no standard treatment exists for your cancer.
- You are in good overall health (able to do daily activities with little help) and your organs are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 3HP-327, for people with advanced solid tumors that have certain changes in the FGFR2 gene and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Hear when a new Solid Tumors With FGFR2 Alterations, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.